Anne d’Andon

403 total citations
20 papers, 241 citations indexed

About

Anne d’Andon is a scholar working on Economics and Econometrics, General Health Professions and Geriatrics and Gerontology. According to data from OpenAlex, Anne d’Andon has authored 20 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 4 papers in General Health Professions and 3 papers in Geriatrics and Gerontology. Recurrent topics in Anne d’Andon's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (11 papers) and Economic and Financial Impacts of Cancer (4 papers). Anne d’Andon is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (11 papers) and Economic and Financial Impacts of Cancer (4 papers). Anne d’Andon collaborates with scholars based in France, Netherlands and United Kingdom. Anne d’Andon's co-authors include Wim Goettsch, Anthonius de Boer, Olaf H. Klungel, Hans L. Hillege, Amr Makady, Páll Jónsson, Steffen Thirstrup, Hubert G. M. Leufkens, Elisabeth George and H.G.M. Leufkens and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Value in Health.

In The Last Decade

Anne d’Andon

19 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne d’Andon France 7 181 51 35 33 23 20 241
Kelly Plueschke Netherlands 7 140 0.8× 25 0.5× 56 1.6× 29 0.9× 25 1.1× 12 279
Ashley Jaksa United States 7 137 0.8× 67 1.3× 64 1.8× 17 0.5× 10 0.4× 31 257
Mona Sabharwal Canada 9 145 0.8× 43 0.8× 15 0.4× 46 1.4× 9 0.4× 14 303
Thomas Grischott Switzerland 9 181 1.0× 51 1.0× 15 0.4× 13 0.4× 16 0.7× 27 344
Martin E. Backhouse United States 14 271 1.5× 120 2.4× 34 1.0× 43 1.3× 6 0.3× 20 384
Catherine I. Starner United States 9 160 0.9× 29 0.6× 7 0.2× 56 1.7× 8 0.3× 15 345
P. O’Neill United Kingdom 6 216 1.2× 81 1.6× 5 0.1× 37 1.1× 9 0.4× 13 270
Kelechi Kalu Olu Switzerland 6 66 0.4× 48 0.9× 26 0.7× 15 0.5× 52 2.3× 6 366
Kirsten Axelsen United States 9 229 1.3× 37 0.7× 6 0.2× 29 0.9× 5 0.2× 14 343
Julia Dunne United States 4 72 0.4× 30 0.6× 36 1.0× 228 6.9× 14 0.6× 5 304

Countries citing papers authored by Anne d’Andon

Since Specialization
Citations

This map shows the geographic impact of Anne d’Andon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne d’Andon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne d’Andon more than expected).

Fields of papers citing papers by Anne d’Andon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne d’Andon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne d’Andon. The network helps show where Anne d’Andon may publish in the future.

Co-authorship network of co-authors of Anne d’Andon

This figure shows the co-authorship network connecting the top 25 collaborators of Anne d’Andon. A scholar is included among the top collaborators of Anne d’Andon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne d’Andon. Anne d’Andon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cucherat, Michel, Silvy Laporte, Jéhan‐Michel Béhier, et al.. (2019). From single-arm studies to externally controlled studies. Methodological considerations and guidelines. Therapies. 75(1). 21–27. 24 indexed citations
2.
Cucherat, Michel, Silvy Laporte, Jéhan‐Michel Béhier, et al.. (2019). Des études mono-bras aux études de comparaison externe. Considérations méthodologiques et recommandations. Therapies. 75(1). 13–19. 1 indexed citations
3.
Thuillez, Christian, et al.. (2019). OP132 What Future For Drugs After An Early Dialogue Procedure?. International Journal of Technology Assessment in Health Care. 35(S1). 30–30. 1 indexed citations
4.
Berdaï, Driss, Karine Szwarcensztein, Anne d’Andon, et al.. (2017). Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases. Therapies. 73(1). 13–24. 5 indexed citations
5.
Albin, Nicolas, et al.. (2017). How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS. Annals of Oncology. 28. v642–v642. 2 indexed citations
6.
Makady, Amr, Páll Jónsson, Anne d’Andon, et al.. (2017). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. PharmacoEconomics. 36(3). 359–368. 75 indexed citations
7.
Berdaï, Driss, Karine Szwarcensztein, Anne d’Andon, et al.. (2017). Demandes d’études post-inscription (EPI), suivi des patients en vie réelle : évolution de la place des bases de données. Therapies. 73(1). 1–12. 2 indexed citations
8.
Albin, Nicolas, et al.. (2017). Cancer drug assessment: What is driving high clinical added value in France?. Journal of Clinical Oncology. 35(15_suppl). 6526–6526. 1 indexed citations
9.
Albin, Nicolas, et al.. (2017). Access and price of cancer drugs: What is happening in France?. Journal of Clinical Oncology. 35(15_suppl). 6623–6623. 1 indexed citations
10.
Degos, Françoise, et al.. (2016). Infection par le virus de l’hépatite C : prise en charge thérapeutique. La Presse Médicale. 45(5). 495–508. 1 indexed citations
11.
d’Andon, Anne, et al.. (2016). Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Annals of Oncology. 27(9). 1768–1775. 44 indexed citations
12.
13.
d’Andon, Anne, et al.. (2016). Bilan rétrospectif des études post-inscription de la commission de la transparence : quelle prise en compte des résultats ?. Revue d Épidémiologie et de Santé Publique. 64. S304–S304. 1 indexed citations
14.
Jeunne, Claire Le, Nathalie Billon, Anne d’Andon, et al.. (2013). Off-label Prescriptions: how to Identify Them, Frame Them, Announce Them and Monitor Them in Practice?. Therapies. 68(4). 233–239. 12 indexed citations
15.
Jeunne, Claire Le, Nathalie Billon, Anne d’Andon, et al.. (2013). Prescriptions hors-AMM : comment en pratique les identifier, les encadrer, informer et les suivre ?. Therapies. 68(4). 225–231. 8 indexed citations
16.
George, Elisabeth, Anne d’Andon, Steffen Thirstrup, et al.. (2012). Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. Value in Health. 15(6). 954–960. 47 indexed citations
17.
Paintaud, Gilles, Marine Diviné, Philippe Lechat, et al.. (2012). Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme. Therapies. 67(4). 319–327. 2 indexed citations
18.
Paintaud, Gilles, Marine Diviné, Philippe Lechat, et al.. (2012). Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety. Therapies. 67(4). 329–337. 2 indexed citations
19.
d’Andon, Anne, et al.. (2005). Le choix entre dialyse péritonéale et hémodialyse : une revue critique de la littérature. Néphrologie & Thérapeutique. 1(4). 213–220. 9 indexed citations
20.
d’Andon, Anne, et al.. (2003). HP3 END STAGE RENAL DISEASE IN FRANCE: PLANNING EVOLUTION OF HEALTH CARE NEEDS USING A MARKOV MODEL. Value in Health. 6(6). 609–609. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelly Plueschke Breakdown of academic impact, for papers by Ashley Jaksa Breakdown of academic impact, for papers by Mona Sabharwal Breakdown of academic impact, for papers by Thomas Grischott Breakdown of academic impact, for papers by Martin E. Backhouse Breakdown of academic impact, for papers by Catherine I. Starner Breakdown of academic impact, for papers by P. O’Neill Breakdown of academic impact, for papers by Kelechi Kalu Olu Breakdown of academic impact, for papers by Kirsten Axelsen Breakdown of academic impact, for papers by Julia Dunne
Rankless by CCL
2026